TPPU treatment of burned mice dampens inflammation and generation of bioactive DHET which impairs neutrophil function

Sci Rep. 2021 Aug 16;11(1):16555. doi: 10.1038/s41598-021-96014-2.

Abstract

Oxylipins modulate the behavior of immune cells in inflammation. Soluble epoxide hydrolase (sEH) converts anti-inflammatory epoxyeicosatrienoic acid (EET) to dihydroxyeicosatrienoic acid (DHET). An sEH-inhibitor, TPPU, has been demonstrated to ameliorate lipopolysaccharide (LPS)- and sepsis-induced inflammation via EETs. The immunomodulatory role of DHET is not well characterized. We hypothesized that TPPU dampens inflammation and that sEH-derived DHET alters neutrophil functionality in burn induced inflammation. Outbred mice were treated with vehicle, TPPU or 14,15-DHET and immediately subjected to either sham or dorsal scald 28% total body surface area burn injury. After 6 and 24 h, interleukin 6 (IL-6) serum levels and neutrophil activation were analyzed. For in vitro analyses, bone marrow derived neutrophil functionality and mRNA expression were examined. In vivo, 14,15-DHET and IL-6 serum concentrations were decreased after burn injury with TPPU administration. In vitro, 14,15-DHET impaired neutrophil chemotaxis, acidification, CXCR1/CXCR2 expression and reactive oxygen species (ROS) production, the latter independent from p38MAPK and PI3K signaling. We conclude that TPPU administration decreases DHET post-burn. Furthermore, DHET downregulates key neutrophil immune functions and mRNA expression. Altogether, these data reveal that TPPU not only increases anti-inflammatory and inflammation resolving EET levels, but also prevents potential impairment of neutrophils by DHET in trauma.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 8,11,14-Eicosatrienoic Acid / analogs & derivatives*
  • 8,11,14-Eicosatrienoic Acid / metabolism
  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use*
  • Burns / drug therapy*
  • Burns / immunology
  • Burns / metabolism
  • Burns / pathology
  • Cytokines / blood
  • Epoxide Hydrolases / antagonists & inhibitors
  • Female
  • Lipopolysaccharides / pharmacology
  • MAP Kinase Signaling System / drug effects
  • Male
  • Mice
  • Mice, Inbred C57BL
  • NADPH Oxidases / metabolism
  • Neutrophils / classification
  • Neutrophils / immunology*
  • Neutrophils / metabolism
  • Phagocytosis / drug effects
  • Phenylurea Compounds / pharmacology
  • Phenylurea Compounds / therapeutic use*
  • Phosphatidylinositol 3-Kinases / biosynthesis
  • Phosphatidylinositol 3-Kinases / genetics
  • Piperidines / pharmacology
  • Piperidines / therapeutic use*
  • Reactive Oxygen Species / metabolism
  • Receptors, Chemokine / physiology
  • Respiratory Burst / drug effects
  • Transcription, Genetic / drug effects
  • p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • p38 Mitogen-Activated Protein Kinases / biosynthesis
  • p38 Mitogen-Activated Protein Kinases / genetics

Substances

  • 1-trifluoromethoxyphenyl-3-(1-propionylpiperidine-4-yl)urea
  • 14,15-dihydroxyeicosatrienoic acid
  • Anti-Inflammatory Agents
  • Cytokines
  • Lipopolysaccharides
  • Phenylurea Compounds
  • Piperidines
  • Reactive Oxygen Species
  • Receptors, Chemokine
  • NADPH Oxidases
  • p38 Mitogen-Activated Protein Kinases
  • Epoxide Hydrolases
  • 8,11,14-Eicosatrienoic Acid